Sunshine Biopharma reported fourth-quarter financial results that outperformed consensus analyst expectations. The company posted an earnings beat of $0.05 per share, alongside revenue figures that came in above projections.
Additional details regarding the financial performance, net income, and forward guidance were not immediately available following the announcement.
